AMT: Difference between revisions
(Created page with "thumb|right α-Methyltryptamine is a long-lasting euphoric stimulant and a psychedelic, a research chemical which was first discovered in the 60s. = History...") |
m (Spelling/Grammatical fixes.) |
||
| (5 intermediate revisions by 4 users not shown) | |||
| Line 1: | Line 1: | ||
[[File:Amt.jpg|thumb|right]] | [[File:Amt.jpg|thumb|right]] | ||
α-Methyltryptamine is a long-lasting euphoric stimulant and a psychedelic, a research chemical which was first discovered in the 60s. | '''α-Methyltryptamine''' is a long-lasting euphoric stimulant and a psychedelic, a research chemical which was first discovered in the 60s. | ||
= History = | == History == | ||
It was originally developed in the USA in the 60s by the Upjohn company during research into anti-depressants, and the alpha-ethylated homologue became available as a commercial anti-depressant in the US (under the name Monase). However, αMT itself was available during the 60s for use as an anti-depressant in 5 and 10mg doses in the Soviet Union, sold under the brand name Indopan. | It was originally developed in the USA in the 60s by the Upjohn company during research into anti-depressants, and the alpha-ethylated homologue became available as a commercial anti-depressant in the US (under the name Monase). However, αMT itself was available during the 60s for use as an anti-depressant in 5 and 10mg doses in the Soviet Union, sold under the brand name Indopan. | ||
As with many research chemicals it was examined by Alexander Shulgin and details of its effects and synthesis were described in the book TiHKAL. Both during his own experiences noted in the entry, and in his further notes drawing from the experiences of others he | As with many research chemicals, it was examined by Alexander Shulgin and details of its effects and synthesis were described in the book TiHKAL. Both during his own experiences noted in the entry, and in his further notes drawing from the experiences of others he concludes that the chemical seems to have a wide variation in many of its properties between users and even individual experiences - particularly in effects and onset. | ||
It was one of the first 'research chemicals' which became widely available on the Internet during the 1990s, and as a result became illegal in the USA in 2003. The drug remained relatively obscure up until this point, though it was used in certain psychotherapeutic studies during the 60s, and there are some reports which suspect recreational use took place as early as the 1960s, as a result of the chemical supply for these studies being diverged. | It was one of the first 'research chemicals' which became widely available on the Internet during the 1990s, and as a result became illegal in the USA in 2003. The drug remained relatively obscure up until this point, though it was used in certain psychotherapeutic studies during the 60s, and there are some reports which suspect recreational use took place as early as the 1960s, as a result of the chemical supply for these studies being diverged. | ||
With the rising popularity of research chemical use on the Internet during the 21st century, it has seen increasing levels of use - and while it remains legal in most countries in the world recent efforts have been made by certain governments to | With the rising popularity of research chemical use on the Internet during the 21st century, it has seen increasing levels of use - and while it remains legal in most countries in the world recent efforts have been made by certain governments to illegalize it. | ||
= Dosage = | == Dosage == | ||
{ | {{#tdose: amt}} | ||
== Duration == | |||
= Duration = | |||
Note: Duration can be significantly longer with higher doses. | Note: Duration can be significantly longer with higher doses. | ||
| Line 55: | Line 35: | ||
|} | |} | ||
= Effects = | == Effects == | ||
== Positive == | === Positive === | ||
* Increase in energy (stimulation) | * Increase in energy (stimulation) | ||
| Line 69: | Line 49: | ||
* Empathogenic qualities | * Empathogenic qualities | ||
== Neutral == | === Neutral === | ||
* General change in consciousness (as with most | * General change in consciousness (as with most psychoactive compounds) | ||
* Blurred vision | * Blurred vision | ||
| Line 85: | Line 65: | ||
* Dry mouth, overstimulated taste, and resulting difficulty eating | * Dry mouth, overstimulated taste, and resulting difficulty eating | ||
* Extreme, vision-obscuring visuals at high doses : "obnoxiously visual" | * Extreme, vision-obscuring visuals at high doses: "obnoxiously visual" | ||
== Negative == | === Negative === | ||
* Anxiety, tension | * Anxiety, tension | ||
| Line 99: | Line 79: | ||
* Headaches | * Headaches | ||
* Jaw clenching ( | * Jaw clenching (Bruxism) | ||
* Extreme confusion at high doses | * Extreme confusion at high doses | ||
=Harm Reduction= | == Harm Reduction == | ||
As a [[stimulants|stimulating]] psychedelic, it carries a heavy body load, and care must be taken to observe physical side-effects such as vasoconstriction, which increase rapidly with dose. Toxic effects have been described at larger doses, so care must be taken to dose accurately. | As a [[stimulants|stimulating]] psychedelic, it carries a heavy body load, and care must be taken to observe physical side-effects such as vasoconstriction, which increase rapidly with dose. Toxic effects have been described at larger doses, so care must be taken to dose accurately. | ||
| Line 113: | Line 93: | ||
See [[Psychedelics#Harm_Reduction|Psychedelic Harm Reduction]] for general information. | See [[Psychedelics#Harm_Reduction|Psychedelic Harm Reduction]] for general information. | ||
= Chemistry and Pharmacology = | == Chemistry and Pharmacology == | ||
αMT acts as a relatively balanced reuptake inhibitor and releasing agent of the main three monoamines; serotonin, norepinephrine, and dopamine, and as a non-selective serotonin receptor agonist. | αMT acts as a relatively balanced reuptake inhibitor and releasing agent of the main three monoamines; serotonin, norepinephrine, and dopamine, and as a non-selective serotonin receptor agonist. | ||
αMT is a reversible MAOI in higher doses (the danger rises exponentially as αMT doses approach 150 mg due to increased monoamine release and increased MAO inhibition), can cause Serotonin Syndrome when combined with monoamine releasers, [[SSRI]]s or other MAO inhibitors. | αMT is a reversible MAOI in higher doses (the danger rises exponentially as αMT doses approach 150 mg due to increased monoamine release and increased MAO inhibition), can cause Serotonin Syndrome when combined with monoamine releasers, [[Antidepressants#SSRIs|SSRI]]s or other MAO inhibitors. | ||
= Legal Status= | == Legal Status == | ||
αMT is scheduled in the US, Australia, Austria, Denmark, Germany, Greece, | αMT is scheduled in the US, Australia, Austria, Denmark, Germany, Greece, | ||
| Line 125: | Line 105: | ||
Hungary, Japan, Lithuania, Russia, Slovakia, Slovenia, Spain, Sweden and soon in the UK as well. | Hungary, Japan, Lithuania, Russia, Slovakia, Slovenia, Spain, Sweden and soon in the UK as well. | ||
= Links = | == Links == | ||
* [https://en.wikipedia.org/wiki/Alpha-Methyltryptamine Wikipedia] | * [https://en.wikipedia.org/wiki/Alpha-Methyltryptamine Wikipedia] | ||
| Line 138: | Line 118: | ||
[[Category:Stimulant]] | [[Category:Stimulant]] | ||
[[Category:Research Chemical]] | |||
Latest revision as of 19:46, 9 June 2017
α-Methyltryptamine is a long-lasting euphoric stimulant and a psychedelic, a research chemical which was first discovered in the 60s.
History
It was originally developed in the USA in the 60s by the Upjohn company during research into anti-depressants, and the alpha-ethylated homologue became available as a commercial anti-depressant in the US (under the name Monase). However, αMT itself was available during the 60s for use as an anti-depressant in 5 and 10mg doses in the Soviet Union, sold under the brand name Indopan.
As with many research chemicals, it was examined by Alexander Shulgin and details of its effects and synthesis were described in the book TiHKAL. Both during his own experiences noted in the entry, and in his further notes drawing from the experiences of others he concludes that the chemical seems to have a wide variation in many of its properties between users and even individual experiences - particularly in effects and onset.
It was one of the first 'research chemicals' which became widely available on the Internet during the 1990s, and as a result became illegal in the USA in 2003. The drug remained relatively obscure up until this point, though it was used in certain psychotherapeutic studies during the 60s, and there are some reports which suspect recreational use took place as early as the 1960s, as a result of the chemical supply for these studies being diverged.
With the rising popularity of research chemical use on the Internet during the 21st century, it has seen increasing levels of use - and while it remains legal in most countries in the world recent efforts have been made by certain governments to illegalize it.
Dosage
{{#tdose: amt}}
Duration
Note: Duration can be significantly longer with higher doses.
| Onset | 30-120 minutes |
| Total | 10-16 hours |
Effects
Positive
- Increase in energy (stimulation)
- Mood lift, smiling
- Visual patterning and closed eye visuals
- Increased awareness & appreciation of music
- Empathogenic qualities
Neutral
- General change in consciousness (as with most psychoactive compounds)
- Blurred vision
- Restlessness
- Yawning
- Dilated pupils
- Decreased appetite
- Dry mouth, overstimulated taste, and resulting difficulty eating
- Extreme, vision-obscuring visuals at high doses: "obnoxiously visual"
Negative
- Anxiety, tension
- Nausea and vomiting
- Decrease in coordination
- Muscle aching
- Headaches
- Jaw clenching (Bruxism)
- Extreme confusion at high doses
Harm Reduction
As a stimulating psychedelic, it carries a heavy body load, and care must be taken to observe physical side-effects such as vasoconstriction, which increase rapidly with dose. Toxic effects have been described at larger doses, so care must be taken to dose accurately.
Many users report experiencing particular nausea when ingesting the drug, which is abated after vomiting. If you feel the need to vomit, do not fight it.
Avoid other MAOIs.
See Psychedelic Harm Reduction for general information.
Chemistry and Pharmacology
αMT acts as a relatively balanced reuptake inhibitor and releasing agent of the main three monoamines; serotonin, norepinephrine, and dopamine, and as a non-selective serotonin receptor agonist.
αMT is a reversible MAOI in higher doses (the danger rises exponentially as αMT doses approach 150 mg due to increased monoamine release and increased MAO inhibition), can cause Serotonin Syndrome when combined with monoamine releasers, SSRIs or other MAO inhibitors.
Legal Status
αMT is scheduled in the US, Australia, Austria, Denmark, Germany, Greece,
Hungary, Japan, Lithuania, Russia, Slovakia, Slovenia, Spain, Sweden and soon in the UK as well.